Octopus Titan VCT plc

Total Voting Rights and Capital

Octopus Titan VCT plc (‘the Company’) announces that as at 30 September 2026 its issued share capital consists of 1,648,217,720 Ordinary shares of 0.1p each. The Company holds no shares in treasury and the total voting rights in the Company are 1,648,217,720.

The above figure of 1,648,217,720 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

For further information please contact:

Rachel Peat
Octopus Company Secretarial Services Limited
Tel: +44 (0)80 0316 2067

LEI: 213800A67IKGG6PVYW75

BLOCK LISTING SIX MONTHLY RETURN

Date:   1 October 2026

1. Name of applicant:   Irish Continental Group plc
2. Name of scheme:  ICG Share Option Plans
3. Period of return:                             From:  1 April 2026 to 30 September 2026
4. Balance of unallotted securities under scheme(s) from previous return: 2,936,561 ICG Units
5. Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
6. Less: Number of securities issued/allotted under scheme(s) during period: Nil
7. Equals: Balance under scheme(s) not yet issued/allotted at end of period: 2,936,561 ICG Units

Name of contact: Brian Holland
Telephone number of contact: +353 1 607 5700

Octopus Future Generations VCT plc

Total Voting Rights and Capital

Octopus Future Generations VCT plc (‘the Company’) announces that as at 30 September 2026 its issued share capital consists of 63,282,656 Ordinary shares of 0.1p each. The Company holds no shares in treasury and the total voting rights in the Company are 63,282,656.

The above figure of 63,282,656 ‬‬‬ may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

For further information please contact:

Ronan Goggin
Octopus Company Secretarial Services Limited
Tel: +44 (0)80 0316 2067

LEI: 213800AL71Z7N2O58N66

Octopus AIM VCT plc

Total Voting Rights and Capital

Octopus AIM VCT plc (‘the Company’) announces that as at 30 September 2026 its issued share capital consists of 249,649,573 Ordinary shares of 1p each. The Company holds no shares in treasury and the total voting rights in the Company are 249,649,573.

The above figure of 249,649,573 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.‬‬‬‬‬‬‬‬

For further information please contact:

Ronan Goggin
Octopus Company Secretarial Services Limited
Tel: +44 (0)80 0316 2067

LEI: 213800C5JHJUQLAFP619

Octopus AIM VCT 2 plc

Total Voting Rights and Capital

Octopus AIM VCT 2 plc (‘the Company’) announces that as at 30 September 2026 its issued share capital consists of 218,720,877 Ordinary shares of 0.01p each. The Company holds no shares in treasury and the total voting rights in the Company are 218,720,877.

The above figure of 218,720,877 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

For further information please contact:

Andrew Humphries
Octopus Company Secretarial Services Limited
Tel: +44 (0)80 0316 2067

LEI: 213800BW27BKJCI35L17

FORESIGHT VENTURES VCT PLC
LEI: 213800R88MRC4Y3OIW86

TRANSACTION IN OWN SECURITIES
1 OCTOBER 2026

The Board of Foresight Ventures VCT plc (“the Company”) announces that on 30 September 2026 the Company purchased for cancellation 1,815,115 ordinary shares of 1p at a gross price of 79.37 pence per share.

In accordance with the FCA’s Disclosure and Transparency Rules sourcebook transitional provision 6, the Company advises that, following this purchase, its capital consists of 103,892,702 ordinary shares of 1p with 103,892,702 voting rights attached.

The Company does not hold any shares in Treasury.

Therefore the total number of voting rights in the Company’s shares is 103,892,702 which may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure and Transparency Rules.

The Company was satisfied that all inside information which the Directors and the Company were previously in receipt of had become publicly available prior to the market purchase being completed. Therefore, the Company was not prohibited from dealing in its own securities.

For further information, please contact:

Company Secretary
Foresight Group LLP
Contact: Stephen Thayer Tel: 0203 667 8100

Investor Relations
Foresight Group LLP
Contact: Andrew James Tel: 0203 667 8181

REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical antibodies from Regeneron

Regeneron to receive $1 billion upfront with potential for up to an additional $7 billion in future milestone payments; companies to equally share development and commercialization costs, as well as any future profits

Regeneron and Sanofi to host a conference call for investors and analysts today at 8:00 am ET/2:00 pm CET

TARRYTOWN, N.Y. and PARIS, Oct. 01, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced an expansion of their long-standing antibody collaboration, adding multiple next-generation, long-acting antibodies to the alliance that has jointly established Dupixent® (dupilumab) as the world-leading treatment for diseases driven by type 2 inflammation. The agreement builds on the companies’ more than 20-year collaboration, through which more than 1.5 million people are currently receiving Dupixent across nine indications, making it one of the most widely used antibody medicines in the world.

“The Regeneron-Sanofi alliance has been one of the most productive in biopharma history. This agreement builds on that foundation to bring the next generation of immunology medicines to patients even faster,” said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron. “By expanding our alliance, we are positioning promising new long-acting antibodies for the kind of rapid, global impact that our shared work on Dupixent has already achieved.”

Under the expanded license and collaboration agreement, the companies will co-develop and co-commercialize four new long-acting, Regeneron-invented antibodies targeting interleukin-13 (IL-13), IL-4xIL-13 bispecific, interleukin-4 (IL-4) and interleukin-4 receptor alpha (IL-4Rα). IL-13 antibody REGN20423 is currently in a Phase 1 clinical trial for atopic dermatitis, and the other three antibodies are expected to enter clinical studies in 2027. Regeneron will also have the option to include in the collaboration Sanofi’s lunsekimig, an investigational bispecific Nanobody® VHH therapy targeting TSLP and IL-13, exercisable upon completion of its Phase 3 trials for chronic obstructive pulmonary disease.

“This is a deliberate first step in igniting Sanofi’s innovation engine. Our longstanding Alliance with Regeneron has transformed the treatment landscape for millions of patients living with diseases driven by type 2 inflammation and created one of the world’s leading immunology businesses,” said Belén Garijo, Chief Executive Officer of Sanofi. “By deepening our collaboration, we will make rapid progress in creating the next generation of meaningful therapies for patients with immune-mediated diseases, while contributing to Sanofi’s long-term future.”

Under the terms of the agreement, Regeneron will receive an upfront payment of $1 billion from Sanofi, with the potential for development, regulatory and commercial milestone payments of up to an additional $7 billion. The companies will share development and commercialization costs for the new programs and will split future profits from these potential products 50:50 on a global basis. Regeneron will lead research and development activities, and Sanofi will lead global commercial efforts. The existing profit-sharing agreement regarding Dupixent will not change.

“The companies’ clinical and commercial alliance dates to 2003 and has resulted in multiple approved medicines to date, including Dupixent which has redefined the standard of care for people with type 2 inflammatory diseases and is now one of the most widely used antibodies for any disease, with over 1.5 million active patients worldwide,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent. “By combining Regeneron’s world-class scientific discovery and antibody development expertise with Sanofi’s global capabilities and reach, we hope to once again deliver the next wave of innovation in immunology.”

The companies have settled their prior collaboration-related litigation.

Conference call for investors and analysts
Regeneron and Sanofi will host a conference call for investors and analysts today at 8:00 am ET/2:00 pm CET. A presentation will be available for download from the Investor Relations section of regeneron.com and sanofi.com when the conference call starts.

Participants may access today’s conference call live via webcast on the ‘Investors and Media’ page of Regeneron’s website at https://investor.regeneron.com/events-and-presentations and on the ‘Upcoming Events’ page of Sanofi’s website at https://www.sanofi.com/en/investors/news-events/upcoming-events. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.

About Dupixent
Dupixent, which was invented using Regeneron’s proprietary VelocImmune® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase 3 studies, establishing that IL-4 and IL-13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases.

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, chronic obstructive pulmonary disease, bullous pemphigoid, and allergic fungal rhinosinusitis in different age populations. In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in phase 3 studies, including chronic pruritus of unknown origin. These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority.

Select Dupixent Safety Information for US Patients
Dupixent is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients. Warnings and precautions include hypersensitivity reactions; conjunctivitis, keratitis, and blepharitis; eosinophilic conditions; acute asthma symptoms or chronic obstructive pulmonary disease or acute deteriorating disease; risk associated with abrupt reduction of corticosteroid dosage; psoriasis; arthralgia and psoriatic arthritis; parasitic (helminth) infections; and avoidance of live vaccines. The most common adverse reactions vary by indication and include injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes viral infection, dry eye, eosinophilia, oropharyngeal pain, insomnia, toothache, gastritis, arthralgia, upper respiratory tract infections, nasopharyngitis, dizziness, myalgia, diarrhea, viral infection, headache, back pain, urinary tract infection, rhinitis, and blurred vision.

Please see full Dupixent Prescribing Information including Patient Information for complete safety information.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases. For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.

Regeneron Media Relations
Christina Chan | +1 914-383-6374 | christina.chan@regeneron.com 
Alexandra Bowie | +1 914-346-0588 | alexandra.bowie@regeneron.com 

Regeneron Investor Relations
Ryan Crowe | +1 914-847-8790 | ryan.crowe@regeneron.com
Mark Hudson | +1 914-847-3482 | mark.hudson@regeneron.com

Sanofi Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Victor Rouault | +1 617 356 4751 | victor.rouault@sanofi.com
Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com
Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com
Ekaterina Pesheva | +1 410 926 6780 | ekaterina.pesheva@sanofi.com

Sanofi Investor Relations
Thomas Kudsk Larsen | +44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Keita Browne | +1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com
Nina Goworek | +1 908 569 7086 | nina.goworek@sanofi.com
Thibaud Châtelet | +33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com

Regeneron Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation the research and clinical programs discussed or referenced in this press release such as those evaluating Regeneron-discovered antibodies targeting interleukin-13 (IL-13), interleukin-4 (IL-4), and interleukin-4 receptor alpha (IL-4Rα) as well as a bispecific antibody targeting IL-4xIL-13; the potential for any license, collaboration, or supply agreement, including Regeneron’s amended license and collaboration agreement with Sanofi discussed in this press release, to be cancelled or terminated without realizing the expected benefits of such agreement; uncertainty of the utilization, market acceptance, and/or commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron’s Products and Regeneron’s Product Candidates (such as those referenced above); the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees (including based on the amended license and collaboration agreement discussed in this press release) may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, such as those referenced above; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates (such as those referenced above) in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy, including in connection with Regeneron’s April 2026 agreements with the U.S. government; other changes in laws, regulations, and policies affecting the healthcare industry; competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the impact of public health outbreaks, epidemics, or pandemics on Regeneron’s business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney’s Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025 and its Form 10-Q for the quarterly period ended June 30, 2026. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron’s media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

Sanofi forward-looking statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future events and economic performance. Words such as “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan,” “can,” “contemplate,” “could,” “is designed to,” “may,” “might,” “potential,” “objective,” “attempt,” “target,” “project,” “strategy,” “strive,” “desire,” “predict,” “forecast,” “ambition,” “guideline,” “seek,” “should,” “will,” “goal,” or the negative of these, and similar expressions are intended to identify forward-looking statements.

Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the U.S Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates; the fact that product candidates if approved may not be commercially successful; unexpected regulatory actions or delays, or government regulation generally; authorities’ decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including “most favored nation” pricing for State Medicaid programs; the future approval and commercial success of therapeutic alternatives; Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation;  trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole.  The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markest Authority (AMF) made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2025 or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements contained herein.

All trademarks mentioned in this press release are the property of the Sanofi group except for VelociSuite and Regeneron Genetics Center.

Regulatory approvals from the Central Bank of the UAE (United Arab Emirates) and the Central Bank of Bahrain complete the change in ownership of Al Futtaim Willis.

Complements broader regional expansion underway with growing presence in UAE and Saudi Arabia.

DUBAI, United Arab Emirates, Oct. 01, 2026 (GLOBE NEWSWIRE) — WTW (NASDAQ: WTW), a leading global advisory, broking and solutions company, today confirmed regulatory approval for a change in the ownership of its longstanding joint venture, UAE-based Al-Futtaim Willis (AFW). Following Al-Futtaim’s sale of its 51% stake in the joint venture, WTW will assume full control of the AFW business.

Pamela Thomson-Hall, Head of International at WTW, said: “WTW’s investment strategy remains acutely focused on optimizing the company’s portfolio globally and pursuing scaled and high-growth broking businesses. This investment will enable us to wholly manage our businesses in Dubai and Bahrain going forward . It further strengthens our strategy and enables us to provide clients in the UAE and wider region with better access to our specialist expertise and global placement capabilities. It also enhances our ability to serve our global benefit management clients through a more consistent delivery approach.”

Head of WTW CEEMEA, Eleni Lykoudi, commented: “This change in ownership structure complements WTW’s recent investments in the Kingdom of Saudi Arabia, where the company recently established insurance and reinsurance broking entities. The integration of AFW will allow our local, regional, and global clients to access WTW’s entire portfolio, enhancing our value proposition in the market. All of this speaks to WTW’s commitment to invest in the Middle East and our enhanced client service offering in the region.”

About WTW

At WTW (NASDAQ: WTW), we provide data-driven, insight-led solutions in the areas of people, risk and capital. Leveraging the global view and local expertise of our colleagues serving 140 countries and markets, we help organizations sharpen their strategy, enhance organizational resilience, motivate their workforce and maximize performance. Working shoulder to shoulder with our clients, we uncover opportunities for sustainable success—and provide perspective that moves you. Learn more at www.wtwco.com

Media Contacts  
Jo Barrett jo.barrett@wtwco.com


Forward Looking Disclaimer

This document contains ‘forward-looking statements’ within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created by those laws. You can identify these statements and other forward-looking statements by words such as ‘may’, ‘will’, ‘would’, ‘commit’, ‘anticipate’, ‘believe’, ‘estimate’, ‘expect’, ‘intend’, ‘plan’, ‘future’, or similar words, expressions or the negative of such terms or other comparable terminology. These forward-looking statements include, but are not limited to, strategic plans and the future of our business, receipt of regulatory approvals and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. All forward-looking disclosure is speculative by its nature.

There are important risks, uncertainties, events and factors that could cause our actual results or performance to differ materially from those in the forward-looking statements contained in this document, including, but not limited to those described under “Risk Factors” in the Company’s most recent 10-K filing and subsequent filings filed with the SEC. The foregoing list of factors is not exhaustive, and new factors may emerge from time to time that could also affect actual performance and results. Although we believe that the assumptions underlying our forward-looking statements are reasonable, any of these assumptions, and therefore also the forward-looking statements based on these assumptions, could themselves prove to be inaccurate. Given the significant uncertainties inherent in the forward-looking statements included in this document, our inclusion of this information is not a representation or guarantee by us that our objectives and plans will be achieved. Our forward-looking statements speak only as of the date made, and we will not update these forward-looking statements unless the securities laws require us to do so. With regard to these risks, uncertainties and assumptions, the forward-looking events discussed in this document may not occur, and we caution you against unduly relying on these forward-looking statements.

IBA to offer QUANTM® Irradiation System solid-target technology to cyclotron users worldwide, scaling local production of radiometals for theranostics

Louvain-la-Neuve, Belgium – October 1st, 2026, 7 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions today announced a new agreement with ARTMS Inc. (a Telix company) for IBA to distribute ARTMS’s proprietary solid‑target cyclotron technology, known as QUANTM® Irradiation System (QIS®), to support the expansion of theranostics worldwide.

With QIS® referenced in FDA filings for multiple approved products, ARTMS is the only solid-target cyclotron technology solution in the U.S. with validated gallium-68 (⁶⁸Ga) and zirconium-89 (89Zr) production. For shorter half-life isotopes such as ⁶⁸Ga, QIS enables decentralized, high-yield, multi-Curie production. Beyond ⁶⁸Ga and 89Zr, ARTMS continues to advance the high-efficiency, large-scale and cost-effective production of other commercially important radiometals, including technetium-99m (99mTc) and copper-64 (64Cu).

Under the partnership agreement, IBA will offer QIS to new and existing cyclotron customers worldwide, so that the accelerator and solid-target capability can be sourced, installed and serviced through a single supplier. QIS remains compatible with other cyclotron platforms, and ARTMS continues to serve its existing customers directly. The collaboration aims to accelerate the availability of innovative diagnostic and therapeutic isotopes to support the expansion of theranostics worldwide, through establishing scalable production infrastructures capable of meeting the rapidly growing needs of healthcare providers and patients.

IBA and Telix are working together to advance the future of radiometal-based medicine through a collaboration that brings together leading capabilities across the radiopharmaceutical value chain. By leveraging their respective strengths, IBA and Telix aim to contribute to a more integrated, reliable, and accessible radiopharmaceutical ecosystem.

Loïk-Maël Nys, President of IBA RadioPharma Solutions commented: “These initiatives reinforce IBA’s strategic vision to support the transformation of nuclear medicine toward a broad theranostic landscape relying on radiometals and emerging therapeutic isotopes. By combining IBA’s expertise in particle acceleration and radiopharmaceutical manufacturing solutions with the complementary capabilities of ARTMS and Telix, we aim to simplify access to advanced production technologies while accelerating innovation across the radiopharmaceutical value chain.” 

Chad Watkins, General Manager Isotope Strategy of Telix Pharmaceuticals, said: “Reliable local supply of gallium-68 and other radiometals is what allows precision oncology to reach more patients. IBA brings the reach and the service capability to put QIS within reach of sites that could not easily access it before.”

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals, and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,300 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com.

About Telix Pharmaceuticals

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease. 

Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X and Facebook.

CONTACTS
Thomas Pevenage
Investor Relations
+32 10 475 890
investorrelations@iba-group.com

Nathalie van Ypersele
Head of Communication and Sustainability

Daniel Ernult
Corporate Communication Manager
+32 10 475 890
communication@iba-group.com

Attachment

Press Release

dsm-firmenich completes €540 million share repurchase program

Kaiseraugst (Switzerland), Maastricht (Netherlands), October 1, 2026

dsm-firmenich, innovators in nutrition, health, and beauty, announces it has completed its €540 million share repurchase program.

On March 12, 2026, the company announced the start of the program for a total amount of €540 million, of which €40 million to cover commitments under the Group’s share-based compensation plans and €500 million to reduce its issued capital.

In accordance with regulations, dsm-firmenich informs the market that during the period from September 28, 2026 up to and including September 30, 2026 a total number of 193,100 shares have been repurchased on its behalf. The shares were repurchased at an average price of €98.62 per share for a total amount of €19.0 million.

This repurchase concludes the share buyback program, with a total number of shares repurchased under this program of 7,169,147 shares at an average price of €75.32 and for a total consideration of €540 million. Of the total, 680,701 shares have been repurchased to cover commitments under the Group’s share-based compensation plans, and 6,488,446 shares have been repurchased for capital reduction purposes.

dsm-firmenich intends to cancel 6,488,446 shares by the end of the first quarter of 2027. This cancellation will reduce the number of issued shares by c. 2.6% from 253,626,947 shares to 247,138,501 shares.

For more detailed information see ‘Daily transaction details Share Repurchase Program announced February 9, 2026’.

For more information, please contact:

dsm-firmenich investor relations enquiries:
Email: investors@dsm-firmenich.com

dsm-firmenich media enquiries:
Email: media@dsm-firmenich.com   

About dsm-firmenich
As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for people and the planet. dsm-firmenich is a Swiss company, listed on Euronext Amsterdam and SIX Swiss Exchange, with operations in almost 60 countries and revenues of more than €9 billion for its Continuing Operations following the divestment of Animal Nutrition & Health. With a diverse, worldwide team of nearly 21,000 employees, we bring progress to life every day, everywhere, for billions of people. www.dsm-firmenich.com

Disclaimer  

This press release does not constitute or form part of, an offer or any solicitation of an offer for securities in any jurisdiction. This press release may contain forward-looking statements with respect to dsm-firmenich’s future. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. This communication contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. The English language version of this press release prevails over other language versions.

Attachment

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.